---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-011002"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:11:22.881461+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology exchanges 6.5M common shares for Series A convertible preferred held by BVF funds

## Summary
- Exchanged 6,475,000 common shares for 647,500 Series A convertible preferred (10:1 conversion ratio).
- Issued under Section 3(a)(9) exemption; no commissions paid.
- Preferred shares have no voting rights; conversion limited to initial 9.99% beneficial ownership cap.
- Post-exchange common outstanding: 39,324,370; preferred convertible into up to 6,457,000 common shares.
- Transaction closed Jan 19, 2023 with Biotechnology Value Fund L.P. and affiliates.

## SEC filing metadata
- accession: 0001193125-23-011002
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312523011002/0001193125-23-011002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312523011002/d399356d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-011002
- JSON: https://secwatch.observer/filing/0001193125-23-011002.json
- Plain text: https://secwatch.observer/filing/0001193125-23-011002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.